Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05079282 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Study sites: 20 to 21 · Eligibility criteria expanded, about 22 words Show 2 more changesShow less
    • Study sites: 20 to 21
    • Eligibility criteria expanded, about 22 words
  2. Changed Sponsor changed: Ono Pharmaceutical Co. Ltd to Ono Pharmaceutical Co., Ltd.
  3. Primary completion date: Mar 31, 2026 to Aug 31, 2027 Study sites: 17 to 20 · Completion date: Mar 31, 2027 to Aug 31, 2028v10 Show 2 more changesShow less
    • Study sites: 17 to 20
    • Completion date: Mar 31, 2027 to Aug 31, 2028
  4. Primary completion date: Jun 1, 2025 to Mar 31, 2026 Study sites: 15 to 17 · Completion date: Jun 1, 2026 to Mar 31, 2027v9 Show 2 more changesShow less
    • Study sites: 15 to 17
    • Completion date: Jun 1, 2026 to Mar 31, 2027
  5. Study sites: 12 to 15v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 11 to 12 Eligibility criteria expanded, about 13 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 13 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv6
  3. Enrollment target: 86 to 217 Site details revised at 2 of 11 sitesv5 Show 1 more changeShow less
    • Site details revised at 2 of 11 sites
  4. Site details revised at 1 of 11 sitesv4
  5. Study sites: 9 to 11v3
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 7 to 9 · Start date changed from estimate of Nov 30, 2021 to Dec 10, 2021v2 Show 2 more changesShow less
    • Study sites: 7 to 9
    • Start date changed from estimate of Nov 30, 2021 to Dec 10, 2021
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Trial Details
NCT Number NCT05079282
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Relapsed or Refractory T Cell Lymphoma
Enrollment 217 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov